Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Pola-R-CHP in Untreated BCL-2+ DLBCL
NCT04790903Phase 1Terminated
- Sponsor
- Roche
- Start
- Jul 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of venetoclax in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants with Dose-Limiting Toxicities. Started Jul 2021; status: terminated.
02
Drugs
venetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04790903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790903.